<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TEICOPLANIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TEICOPLANIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication"><ph outputclass="organism"> <i>Clostridium difficile</i> </ph> infection</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                100&#8211;200 mg twice daily for 10&#8211;14 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Serious infections caused by Gram-positive bacteria (e.g. complicated skin and soft tissue infections, pneumonia)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 70 kg)</strong><br/>
                Initially 400 mg every 12 hours for 3 doses, followed by 400 mg once daily.</li>
              <li class="dose adult"><strong>For adults (body-weight 70 kg and above)</strong><br/>
                Initially 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Streptococcal or enterococcal endocarditis (in combination with another antibacterial)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg/kg every 12 hours for 3&#8211;5 doses, then 10 mg/kg once daily, subsequent doses can be given by intramuscular injection.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bone and joint infections</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 12 mg/kg every 12 hours for 3&#8211;5 doses, then 12 mg/kg once daily subsequent doses can be given by intramuscular injection, increased risk of fever and rash with doses of 12 mg/kg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Surgical prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg, to be administered up to 30 minutes before the procedure.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Surgical prophylaxis in open fractures</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg, to be administered up to 30 minutes before skeletal stabilisation and definitive soft-tissue closure.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Peritonitis associated with peritoneal dialysis (added to dialysis fluid)</span>,
            </h4>
            <p class="specificity"><span class="route">By intraperitoneal infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult local protocol).</li>
            </ul>
          </section>
        </section>
        
        
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>Teicoplanin should <b>not</b> be given by mouth for systemic infections because it is not absorbed significantly.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>The glycopeptide antibiotic <b>teicoplanin</b> has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of <ph outputclass="organism">
            <i>Staphylococcus aureus</i>
            </ph> with reduced susceptibility to glycopeptides and increasing reports of glycopeptide-resistant enterococci. Teicoplanin is similar to vancomycin, but has a significantly longer duration of action, allowing once daily administration after the loading dose.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises use only if potential benefit outweighs risk.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Use normal dose regimen on days 1&#8211;4, then use normal maintenance dose every 48 hours if eGFR 30&#8211;80&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and use normal maintenance dose every 72 hours if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Pruritus, rash,
              </p>
              <p>
                <strong>uncommon:</strong> Bronchospasm, diarrhoea, dizziness, eosinophilia, fever, headache, leucopenia, mild hearing loss, nausea, thrombocytopenia, thrombophlebitis, tinnitus, vestibular disorders, vomiting,
              </p>
              <p>
                <strong>notKnown:</strong> Exfoliative dermatitis, nephrotoxicity, renal failure, Stevens-Johnson syndrome, toxic epidermal necrolysis,
              </p>
        
        
            <section class="advice">
                <h3>Nephrotoxicity</h3>
              <p>Teicoplanin is associated with a lower incidence of nephrotoxicity than vancomycin.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For intravenous infusion (<i>Targocid</i>
            <tm tmtype="reg"/>), give intermittently in Glucose 5% <i>or</i> Sodium chloride 0.9%; reconstitute initially with water for injections provided; infuse over 30 minutes. Continuous infusion not usually recommended.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Injection can be used to prepare solution for oral administration.</p>
            </section>
      </section>






      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Plasma-teicoplanin concentration is not measured routinely because a relationship between plasma concentration and toxicity has not been established. However, the plasma-teicoplanin concentration can be used to optimise parenteral treatment in severe sepsis or burns, deep-seated staphylococcal infection (including bone and joint infection), endocarditis and in intravenous drug abusers. Pre-dose (&#8216;trough&#8217;) concentrations should be greater than 15&#8239;mg/litre (greater than 20&#8239;mg/litre in endocarditis or deep-seated infection such as bone and joint infection), but less than 60&#8239;mg/litre.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Plasma-teicoplanin concentration should be measured in elderly patients.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Blood counts and liver and kidney function tests required.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Teicoplanin doses in BNF may differ from those in product literature.</p>
            </section>
            <section class="unlicensedUse">
              <p>Not licensed for surgical prophylaxis.</p>
            </section>
      </section>









      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Caution if history of vancomycin sensitivity.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TEICOPLANIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,

            <div id="PHP75311"><a href="../medicinalForm/PHP75311.html" data-target="#PHP75311" data-action="load">Powder and solvent for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
